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easily be obtained during tidal breathing even 
in patients with severe airflow limitation. In the 
past two decades numerous disease markers have 
been identified in EBC of patients with COPD;1-5 
however, finding the role for this sampling tech-
nique in the clinical practice is still underway.
As a reflection of the interest from the research 
and clinical communities, an international task 
force report on EBC was endorsed by the Euro-
pean Respiratory Society and the American Tho-
racic Society in 2005, and a technical standard 
chronic obstructive pulmonary disease (COPD) is associated with airway inflamma-
tion, which leads to small airways disease and pa-
renchymal destruction. Assessing airway inflam-
mation potentially contributes to disease monitor-
ing and facilitate personalized therapy. Inflamma-
tory markers can be measured in airway samples 
including induced sputum and exhaled breath, 
which are collected semi- or non-invasively, 
therefore imposing minimal risk and discomfort 
to patients. Exhaled breath condensate (EBC) can 
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vage, induced sputum) is that it is completely 
non-invasive and it samples (at least partly) the 
airway lining fluid (ALF), thereby reflecting 
physiological and pathological processes in the 
lower airways. Non-volatile substances of EBC 
can be released as respiratory droplets (aerosols 
or aerosolized particles) from the ALF. The for-
mation and origin of these respiratory droplets 
within the airways are still under debate.
A likely model is the so-called bronchiole 
fluid film burst concept, which puts forward 
that exhaled particles are mainly formed in the 
peripheral airways. At the end of expiration, 
bronchioles are contracted and blocked, but they 
reopen during inhalation, which generates a tran-
sient rupture in ALF to release aerosols. These 
droplets are transported to the alveoli by the end 
of inspiration and then exhaled. The number of 
exhaled aerosol particles is increased by rapid 
inhalation, deep exhalation and elevated minute 
ventilation, and it shows high inter-individual 
variability.3, 8
Contamination of EBC from the oral cavity and 
upper airways
Constituents of EBC are only partly derived from 
the lower airways as the sample can be contami-
nated from other organs including the pharynx, 
oral cavities, salivary glands and nasal airways. 
Therefore, contamination of some EBC markers 
measured in COPD studies was tested.
Effros et al. implicated that EBC acidification 
document on the topic was published in 2017.4, 5 
These and other publications underline the meth-
odological difficulties of this approach, such as 
sample analysis and data interpretation.2, 3 The 
methodological and clinical details on EBC anal-
ysis in various pulmonary and extrapulmonary 
diseases are detailed in these documents.
In the current review, we focus on exhaled 
breath condensate findings from studies on pa-
tients with COPD. We introduce the sampling 
technique, systematically assess technical is-
sues (sample collection, confounding factors, 
detection methods, marker variability), identify 
markers detected in COPD and summarise recent 
knowledge with the aim to highlight current and 
future application of EBC biomarkers in COPD.
Origin and formation 
of EBC constituents
Source of EBC components
During sample collection, subjects are breathing 
normally inhaling through their nose or mouth 
and their exhaled breath is cooled down on a cold 
surface to generate the condensate fluid. Air is 
fully saturated with water vapour in the airways, 
therefore the collected condensate fluid is a highly 
diluted solution, >99% of its composition is H2O. 
Other compounds are either volatile molecules or 
non-volatile substances, which are added to the 
breath in the lower and upper airways, pharynx, 
oral cavity and salivary glands (Figure 1). How-
ever, the detection of water soluble volatiles in 
EBC in their non-volatile form may be mislead-
ing due to their variable distribution between the 
condensate fluid, saliva and exhaled air.
Some compounds originate predominantly 
from the lower airways, as it was shown for ad-
enosine, adenosine triphosphate (ATP), nitrate, 
thromboxane B2 (TXB2) and pH measurements 
in patients with tracheostomy or endotracheal 
tube. Other molecules, such as ammonia or ni-
trate demonstrated upper airway origin.5-7
Formation of respiratory droplets from the air-
way lining fluid in the lower airways
The main advantage of the EBC technique com-
pared to other options (e.g. bronchoalveolar la- Figure 1.—Origin of exhaled components in EBC.
nasal cavity
oral cavity and 
salivary glands
Oropharynx
Bronchi 
and alveoli
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substances in the ambient air can contaminate 
the condensate fluid, food ingestion can modify 
airways production of molecules, and the sample 
can also be contaminated by the collection de-
vices and during processing.
A recent study has shown that EBC hydro-
gen peroxide (H2o2) levels are significantly af-
fected by environmental H2o2.16 When proteins 
were identified in EBC with gel electrophoresis, 
skin keratins were found to be the most abun-
dant components, most probably a contaminant 
of ambient air inhaled during EBC collection.17 
Authors could decrease the quantity of these con-
taminants using compressed air for inhalation 
during sample collection.
Utmost attention should be paid to sample 
collection and processing if researchers want to 
measure nitric oxides in EBC. High amounts of 
food rich in nitrate modify the concentration of 
nitrate and to a higher extent also nitrite levels 
in EBC.7 Furthermore, it is known that nitrate 
is a common laboratory contaminant, and inap-
propriate cleaning of the collection device or 
the contact of sampling equipment with skin or 
gloves during EBC collection and analysis can 
cause a significant and false increase in the con-
centration of nitric oxide metabolites.18 even 
storage of the collection device on room air for 
a longer period before EBC collection can cause 
artificially elevated nitrite concentration in col-
lected samples.19 In addition, sample containers 
might also emit nitrate/nitrite into the condensate 
fluid, therefore sample analysis should be per-
formed as soon as possible after collection.5
The effect of disinfecting reusable collecting 
devices on EBC metabolomic profile using nu-
clear magnetic resonance (NMR) spectroscopy 
was investigated. The authors found that the dis-
infectant protocol causes no artificial alteration 
in the NMR signals, and it had no negative effect 
on the discriminating potential of this technique 
for COPD.20 However, another group reported 
significant effects of the cleansing protocol on 
the EBC profile and they therefore suggested the 
use of non-reusable collection parts for NMR 
analysis.21
A study analysing EBC of normal controls 
with liquid chromatography and mass spectrom-
etry as a proteomic approach found that ten pro-
in COPD may reflect salivary rather than airway 
acidification.9 Supporting this, mouthwash with 
antibacterial chlorhexidine-digluconate prevent-
ed a reduction in EBC pH induced by drinking 
sugary drink.10
Salivary source for leukotriene B4 (LTB4) in 
EBC was implicated as the mediator could be 
detected only in 4 samples out of 102 that were 
contaminated with saliva as measured with amy-
lase activity.11
A percentage of 63-71 of proteins found in 
low quantity in EBC can also be detected in 
higher amounts in saliva as shown by proteomic 
analysis of samples collected from healthy vol-
unteers. Hence, the authors implicated that EBC 
proteins are likely to have salivary rather than 
lower airway origin.12 in contrary, another study 
also using proteomic approach identified 153 
proteins as reliable “core” proteins in EBC, and 
only eight of them are expressed specifically in 
salivary glands.13
EBC nitrite concentration was lowered by an-
tibacterial washing of the oropharynx, which sug-
gest that formation of nitrite from nitrate takes 
place in the oral cavity and salivary glands, and 
it involves bacterial activity.7 Hence, rinsing the 
oral cavity with an antibacterial solution before 
EBC collection should be advised if nitric oxides 
are wished to be measured.
Metabolomic profile of saliva was tested us-
ing nuclear magnetic resonance (NMR) spectros-
copy, and it could be significantly distinguished 
from the profile of EBC samples in patients with 
COPD.14
Inflammation in the nose and nasal sinuses can 
influence EBC composition if the sample is col-
lected via inhalation through the nose, as respira-
tory droplets from the nasal airway lining fluid 
can be released and exhaled. It was shown that 
concentrations of nitrite, nitrate, TXB2, ammonia 
were not different in EBC samples collected with 
nasal and oral inhalation routes in healthy con-
trols, but adenosine level was increased in EBC 
collected during nasal inhalation in patients with 
allergic rhinitis.5, 15
Contamination of EBC from external sources
The presence of substances in EBC is not linked 
to an airway biological process in some cases as 
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of healthy subjects,30 and it also increases EBC 
H2o2 levels in COPD.31 It was, in addition, dem-
onstrated that drinking sparkling water supple-
mented with sugar or coca cola in 1 hour prior to 
EBC collection influences pH values.32
Gastro-oesophageal reflux disease (GORD) is 
a common comorbidity in obstructive lung dis-
eases. Lower 33 and similar 34 EBC pH was also 
reported in patients suffering from concomitant 
COPD and GORD. In addition, EBC pepsin lev-
els were significantly higher in those COPD pa-
tients who had reflux as reported by one study.34 
However, another group found no difference in 
EBC pepsin concentration in COPD patients 
with and without GORD.35
Technical issues of sample collection 
and respiratory droplet dilution
Collection devices
Several collection devices, either commercially 
available or custom-made, have been used for re-
search and clinical purposes. These instruments 
differ from each other in many aspects including 
material of the condensing surface (e.g. plastic, 
Teflon, glass or aluminium), condensing temper-
ature (between -20 °C and -80 °C), stability of 
condensing temperature during collection, por-
tability, re-usability, ability to separately collect 
fractions during tidal breathing. Depending on 
their chemical properties, molecules in the con-
densate fluid are trapped in the various condens-
ing systems differently.4 in line with this, coating 
the collection surface with albumin yielded a bet-
ter mediator recovery.36 Inter-device differences 
in the detectability and quantity of total protein 
content,37, 38 albumin,39 alpha-1-antitrypsin,38 
8-isoprostane,39, 40 H2o2,40 cysteinyl leukotrienes 
(cys-LT),37 interleukins (IL)-2, -4, -5, -13,40 tu-
mour necrosis factor-α (TNF-α) 40 and pH 37, 41-43 
have been reported. In addition to the influence 
of the coating material, the condensing tempera-
ture also contributes to the variability in EBC 
markers, as shown for pH readings.37
Dilution of respiratory droplets in EBC
Exhaled breath condensate is a very dilute liq-
uid. More than 99% of its water content origi-
teins out of 153 detected in EBC were contami-
nants of samples processing.13
Adenosine triphosphate (ATP) can be found in 
all organic material (live or dead), and on labora-
tory surfaces and human skin. Therefore, EBC for 
purine analysis should be collected in non-reusable 
or sterile equipment, and samples should be pro-
cessed with caution to avoid external contamina-
tion. ATP can be found in high concentration in 
saliva, therefore salivary contamination in EBC 
should be tested when measuring purine mediators.
Clinical confounding factors 
relevant for EBC studies in COPD
Current cigarette smoking, even without con-
comitant COPD, can influence inflammatory me-
diator concentrations in EBC and confound data 
interpretation. However, the effect of smoking on 
EBC biomarkers is not consistent. Elevated con-
centration of H2o2, 8-isoprostane and nitrotyro-
sine were reported in smokers,5, 22 but cigarette 
smoke-induced increase in EBC nitrotyrosine was 
not confirmed by another study.5 Smoking two 
cigarettes induced a transient increase in EBC ni-
trate concentration 5 in healthy volunteers. There 
was a direct correlation between smoking and sur-
factant protein D concentration, while an indirect 
relationship was observed with club cell protein 
level.23 In contrast, acute smoking did not affect 
EBC IL-1β, tumor necrosis factor-alpha (TNF-α) 
or malondialdehyde (MDA) concentrations in 
control subjects and patients.24 In addition, MDA 
levels were similar in smokers and non-smokers.22 
acute 25 or chronic 26 smoking did not affect EBC 
IL-8 levels. Metabolomic fingerprints of smokers, 
patients with COPD and pulmonary Langerhans 
cell histiocytosis, who were current smokers with 
a significant smoking history, could be differenti-
ated suggesting that smoking does not mask the 
specific disease metabolotypes.27
Effects of physiological variations and patient-
related activities on EBC markers in COPD have 
also been studied. H2o2 concentration showed 
diurnal variability in patients with COPD,28 and 
it was strongly affected by the respiratory pat-
tern, necessitating the need for controlled breath-
ing maneuvers in case-control studies.29 Exer-
cise leads to a sustained elevation in EBC pH 
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false positive mediator concentrations in EBC,50 
as these systems are developed for detection in 
the complex matrices of serum, plasma or cell 
culture media. The authors suggest adjustment of 
EBC by adding a proteinacious lyophilized ma-
terial to samples to prevent false detection sig-
nals in EIA. The lack of adjustment could be a 
reason for a high within-assay variability for EIA 
on LTB4 and 8-isoprostane, which showed that 
the mean coefficient of variation (CV) in EBC 
samples was 18.2% and 29.2% in stable COPD.1 
Similarly, the within-assay variability of cys-LT 
concentration in EBC from control volunteers 
was 19.6%.1
Malondialdehyde (MDA) was measured with 
high-pressure liquid chromatography and with 
the more sensitive method of liquid chromatog-
raphy and tandem mass spectrometry.51, 52 al-
though the lower limit of detection was not re-
ported for the latter method, it enabled the quan-
tification of much lower concentrations.
Complex detection techniques allow multi-
marker screening of EBC with high sensitivity. 
Mass spectrometry-based measurement proto-
cols for oxidative stress markers and leukotri-
enes could reach detection and quantification 
limits in the low pg/ml range with >90% ac-
curacy in EBC from control subjects,53, 54 but 
data on COPD are still lacking. Additionally, 
a mass spectrometry protocol was developed 
for the measurement of adenosine and adenine 
purines accompanied with the detection of urea 
to assess dilution of ALF with good within-as-
say reproducibility.47 Metabolomic profiling in 
EBC has been performed with various methods. 
With NMR spectroscopy the fingerprint of pa-
tients with COPD could be distinguished from 
controls;14, 20 however, another group found 
that this method was not sensitive enough to 
pick up important EBC signals, and proposed 
a mass spectrometric protocol as the detection 
method.21
Concentration of EBC samples to increase bio-
marker levels
A main challenge for the reliable detection of 
EBC components is their low concentration in 
the sample. This could be overcome by sample 
concentration including lyophilisation, when all 
nates from the alveolar space which mixes with 
the respiratory droplets liberated from the airway 
wall. Since the ratio of alveolar and bronchial 
water source is variable, the airway concentra-
tion of the investigated mediator cannot be esti-
mated simply from its EBC content. Therefore, 
it is suggested to determine an indicator repre-
senting the rate of respiratory droplet dilution in 
each condensate sample. Such indicator needs 
to be reliably measurable in EBC and must 
have a known airway concentration. Methods 
developed to normalize EBC concentration for 
dilution include the measurement of exhaled 
ions,5, 44 urea,44 proteins 45 or conductance of ly-
ophilized 44 or vacuum evaporated 6, 46 samples. 
Theoretically, dilution may affect the concentra-
tion of water-soluble non-volatile molecules and 
by assessing its magnitude the airway level of the 
mediator can be calculated from its concentra-
tion in EBC.46, 47 However, dilution influences 
EBC pH as well.48 It is still strongly debated if 
EBC studies should routinely apply correction 
on dilution.4 Of note, no difference was shown 
in the magnitude of respiratory droplet dilution 
between COPD and health.49
Difficulties of biomarker 
measurements in EBC
Sensitivity and accuracy of detection methods 
used in EBC analysis
as breath condensate is a highly diluted solution, 
which contains the mediator of interest in small 
amounts, sensitive methods are required for de-
tection and quantification. In addition, being a 
water-based solution, EBC is not an optimal ma-
trix for most commercially available assay sys-
tems that are optimized for samples with more 
complex constituents. The high intra-subject and 
within-subject variation described for many EBC 
mediators can in part be attributed to an inappro-
priate choice of methods for detection.4, 5 Here, 
we enumerate advantages and disadvantages for 
exemplary assay systems, commonly used in 
studies on COPD.
It was elegantly shown that enzyme-linked 
immune assays (EIA), used for measuring cy-
tokines in many past publications, can provide 
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subject variation, most probably due to inter- and 
intra-assay variability. Therefore this method for 
increasing marker stability was not advised by 
the authors.58
Stability of nitrite in EBC at room temperature 
was studied in children with respiratory diseases 
(asthma, cystic fibrosis). The mean CV for ni-
trite concentration after 1 and 3 hours of storage 
ranged 0-33%.19 For optimal stability, samples 
should be kept cold (<8 °C) and concentration 
of nitric oxides should be determined within 24 
hours, or samples can be frozen, but repeated 
freeze-thaw cycles should be avoided before 
measurement.15
MDA was stable for 2 weeks at 4°C in 
EBC collected from controls and patients with 
COPD.51
The addition of protein to EBC may prevent 
the decay of the marker of interest, however, it 
should be tested for each mediator.5
Intra-subject variability of EBC marker con-
centrations in COPD
Within-day and between day variabilities of 
EBC biomarkers measured in COPD are gener-
ally poor, and not systematically studied for all 
mediators.
Both within- and between-day variations in 
EBC pH of stable COPD patients were signifi-
cant, largely exceeding intra-sample variabil-
ity.56 The authors found no correlation between 
the degree of variability and clinical factors such 
as inhaled corticosteroid use, age and FEV1. 
The between-day variability of EBC pH was 
higher in current smokers than in non-smokers 
as assessed by six samplings in a 1-month period 
(mean variance 0.8 vs. 0.03), with acute smoking 
significantly contributing to this variation.57
Concentration of LTB4 and 8-isoprostane 
in EBC as measured with EIA demonstrated a 
significant within-subject variability in stable 
COPD (within-day CV: 47.7% and 65.3%, be-
tween-day CV: 75.7% and 79.1%, respectively).1
On one hand, between-day variability of EBC 
MDA concentration was considerable (in the 
range of mean group values) in stable COPD 
when measured with high pressure liquid chro-
matography.51 on the other hand, when liquid 
chromatography and mass spectrometry was 
free water is removed from the frozen sample but 
solutes remain to be concentrated.2 This method 
has been successfully used to detect multiple 
cytokines with cytometric bead array in COPD 
patients 55 when samples were 40 times concen-
trated. Of note, cytokines could be detected only 
in a small fraction of concentrated EBC samples 
from controls and stable COPD patients, with 
a higher detection rate in exacerbated patients. 
Intra-assay and inter-assay reproducibility for 
the individual markers varied in 90-97% and 80-
93%, respectively. It must be highlighted that af-
ter sample concentration cytokine concentrations 
in controls and stable patients were still around 
the manufacturer’s assay detection limit; howev-
er, detection limits in EBC matrix have not been 
established.
Lyophilisation of pooled samples (600x con-
centration) enabled the detailed characterization 
of the EBC proteome;13 nonetheless, a proto-
col for the concentration of individual samples 
should be developed for clinical studies. Simi-
larly, oxidative stress molecules and leukotrienes 
could successfully and reliably be measured and 
quantified in lyophilised and concentrated EBC 
samples.53, 54 as an alternative to lyophilisation, 
frozen samples can be evaporated in a vacuum 
system.6
Stability of EBC markers during storage
Data on biomarker stability are only scarcely 
available in COPD, and therefore mainly avail-
able findings of relevant mediators from control 
subjects are discussed below.
EBC pH was stable at room temperature for 
3 hours, but within-sample variability increased 
when freezing samples for 3 months, but it was 
still comparable to within-sample variation in 
freshly collected EBC.56 Similarly, no significant 
influence of short- and long-term (from 3 months 
up to 2 years) storage on EBC pH was found in 
samples collected from a control group of non-
smokers and smokers.57
EBC cys-LT concentration considerably de-
creased after 3 months of storage at -80 °C, 
which could be prevented by pretreatment of the 
sample with 0.2% formic acid in methanol fol-
lowing solid-phase extraction before freezing. 
However, mediator recovery showed high inter-
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but it is also affected by volatile gases and bases. 
Most notably, end tidal carbon dioxide influences 
condensate pH significantly. To overcome this 
effect, two methods were developed: Bubbling 
with an inert gas (i.e. argon) and the carbon di-
oxide loading technique.59 Due to considerable 
variation in pH values yielded by neat, argon-
deaerated and carbon dioxide-loaded sample 
measurements, results using different protocols 
should be compared with caution.
Both lower and similar EBC pH values were 
reported when stable COPD patients were com-
pared to control subjects;1, 2, 9, 25, 33, 43, 60, 61 how-
ever, control groups in these studies showed 
considerable heterogeneity consisting of non-
smokers, ex- or current smokers and a mixed 
population. This is highly important, as some 
publications demonstrated reduced EBC pH val-
ue in smokers compared to non-smokers.25, 43, 60 
Supporting this, condensate pH was lower in 
COPD than in non-smoking controls, but not in 
relation to smokers.60 Interestingly, acute smok-
ing did not affect EBC pH.25
Analysing the relationship between EBC pH 
and measures of COPD severity, a direct rela-
tionship was reported with FEV1 and sputum 
neutrophilia, however other studies showed no 
correlation with lung function,1, 43, 56, 60, 61 sputum 
leukocyte counts,60 emphysematous phenotype 62 
or exacerbation frequency.33 EBC pH was not 
different in COPD patients in exacerbation,25, 43 
nor did it change with exacerbation recovery.43
These data suggest that EBC pH is not a reli-
able disease marker in COPD, and it is not as-
sociated with clinical stability or a disease phe-
notype.
used, the between-day coefficient of variation of 
MDA concentration was only 8.2% in controls.52 
However, using the same detection technique the 
between-day mean coefficient of variation of a set 
of aldehydes in smokers ranged between 12.6% 
and 37.4%, for MDA being 18.5%.2 Likewise, 
between-day CV of EBC H2o2 concentration in 
stable COPD over 21-day interval was 45%.28
Both within-day and between-day variability 
in EBC nitrite concentration were considerable 
in healthy adults, and within-day fluctuations 
in mediator concentration exceeded that of be-
tween-day.19 Between-day variability of EBC 
ATP concentration in control subjects was also 
high, showing a CV of 53% as measured using 
luminometry.6 Nonetheless, the metabolomic 
profile of EBC as measured by NMR showed 
good within-days stability in COPD.14 This sug-
gests that highly sensitive methods are needed 
to achieve good quality control in EBC analysis. 
Methodological challenges and pitfalls of sam-
ple collection and analysis in past COPD studies 
are highlighted in Table I.
EBC biomarkers in COPD
Condensate fluid pH
Airway acidity plays a key role in various ele-
ments of COPD pathology, including epithelial 
and ciliary dysfunction, bronchoconstriction, 
increased mucus production and impaired anti-
microbial defence.59 EBC pH can easily be mea-
sured with blood gas analysers or pH electrodes. 
However, the pH value of the condensate fluid 
is determined not only by airway droplet acidity, 
Table I.—Methodological difficulties and pitfalls during collection and analysis of EBC samples in past studies in 
COPD.
Patient-related confounders Sample collection and processing Measurement of mediators
Variable smoking status of controls and 
patients
Contaminants from inhaled air Lack of sample concentration required for 
most commercial assays
Possible effect of comorbidities Effect of breathing pattern on biomarkers Detection methods not sensitive enough 
for mediator detection
Food ingestion, drinking or exercise prior 
to sampling
Remnants of disinfectant on collection 
device
Measurement protocol not optimized for 
EBC matrix
Uncontrolled activity of oral bacteria Not ideal collection surface and 
temperature
variable and high within- and between-
subject variation
Presence of upper airway inflammation External contamination during 
processing and measurement
No systematic control for mediator 
contamination outside the lower airways
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between COPD patients with and without car-
diovascular disease.72 Mediator concentration 
did not change following inhaled treatment with 
either corticosteroid 73 or tiotropium.74
The level of MDA was increased in COPD 
compared to controls and also in relation to pa-
tients with asthma and bronchiectasis,52, 63 and 
significantly correlated with lung function in 
COPD.63 However, other studies reported no dif-
ference.22, 51 There was no difference in MDA 
levels between stable and exacerbated COPD 
patients.51
Hydrogen peroxide and 8-isoprostane con-
centration is increased in EBC in stable COPD, 
and might reflect disease activity, but they do not 
seem to respond to inhaled treatment. The clini-
cal relevance of measuring EBC MDA concen-
tration in COPD is questionable.
Markers of nitrative stress
Nitric oxide (NO), a free radical gas, is generated 
by nitric oxide synthases in the airway epithe-
lium and inflammatory cells. In the presence of 
superoxide anion, a mediator in oxidative stress, 
NO is rapidly converted into peroxynitrate, 
which via nitration damages proteins to form 
nitrosothiol components. Alternatively, NO can 
be oxidized into nitrite (NO2-) and nitrate (NO3). 
Peroxynitrate, nitrosothiols and nitrate/nitrite 
can be measured in EBC to assess the burden of 
airway nitrative stress.
Nitrate concentration was not different be-
tween stable patients and control subjects or be-
tween stable and exacerbated patients.1, 18 Some 
authors suggested that the high variability in EBC 
nitrate concentrations was related to contamina-
tion during sample collection. On the contrary, 
nitrite concentration was increased in COPD and 
showed a positive correlation with disease sever-
ity.55 Another study confirmed elevated nitrite 
concentration in stable COPD compared to never 
smokers and smokers,2 but it was contradicted 
by the finding that elevated nitrite concentration 
was observed only in exacerbated patients, but 
not in stable condition.18 Furthermore, the cumu-
lative measurement of nitrite/nitrate (nitric ox-
ides) showed similar concentrations in patients 
and controls. There was no difference either 
when groups were subdivided into smokers and 
Markers of oxidative stress
COPD is characterised by enhanced oxidative 
stress originating from exogenous factors (i.e. 
smoking, hypoxia) as well as endogenous bur-
den (reactive oxygen species generated by in-
flammatory cells). Numerous studies have aimed 
to analyse stable markers of oxidative stress in 
EBC, most notably H2o2, 8-isoprostane and 
malondialdehyde.
Previous studies reported contradictory find-
ings regarding a change in EBC H2o2 con-
centration in stable COPD compared to con-
trols,1, 22, 61, 63 and there was a significant indirect 
relationship with FEV1 reported by some, but not 
all studies.1, 22, 61 In addition, H2o2 levels were 
related to symptoms burden as assessed with the 
COPD Assessment Test.61 Compared to stable 
disease, a further elevation in EBC H2o2 concen-
trations was reported during exacerbation,64 with 
significant reduction with resolution.65 However, 
another study noted no change during recovery.66 
Treatment with inhaled corticosteroids decreased 
EBC H2o2 levels in one,67 but not in another 
study.68
EBC 8-isoprostane levels were elevated in 
stable COPD.65, 69 There was a further increase 
during exacerbation,26, 70 and it decreased with 
resolution.65 However, the effect of smoking 
needs to be considered when interpreting data. 
elevated, but also unaltered 8-isoprostane con-
centrations were reported in smokers.22, 26 in 
addition, 8-isoprostane was associated with 
smoking intensity in COPD.71 in line with this, 
8-isoprostane levels were increased in COPD 
compared to non-smokers without a significant 
difference when comparing with smokers with-
out COPD.22 Analyzing the measures of COPD 
severity, a significant correlation was noted be-
tween EBC 8-isoprostane concentration and the 
degree of emphysema;2 however, this has not 
been confirmed by another study.62 There was 
an association with lung function;71 however, 
others reported no correlation between this me-
diator and disease severity.22, 69 in addition, high 
EBC 8-isoprostane levels were associated with 
dynamic hyperinflation,71 high BODE Index 71 
and low arterial pressure of oxygen.71 There 
was no difference in EBC 8-isoprostane levels 
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with COPD compared to controls,65 while no dif-
ference was found for other lipid mediators such 
as LTE4 or PGD2-methoxime.79 Cys-LT concen-
tration was reduced in convalescence of a COPD 
exacerbation,65 but it did not respond to therapy 
with ICS.73 Thromboxane B2 was not detectable 
in EBC using EIA.79
Among the arachidonic acid metabolites EBC 
LTB4 is the most studied mediator, which seems 
to be a marker for monitoring airway inflam-
mation;11 however, salivary contamination is a 
potential confounder, which should be system-
atically controlled in studies. Profiling of me-
tabolites using a mass spectrometry-based ap-
proach might aid the reliable detection and better 
interpretation of the role of arachidonic acid sub-
stances in COPD.
Proteins
A plethora of proteins, including cytokines, che-
mokines, enzymes and soluble receptors, sus-
pected of involvement in airway inflammation in 
COPD, were detected in condensate fluid as sin-
gle markers, mostly measured with immunoas-
says. In general, the results of EBC protein mea-
surements are very variable and contradictory, 
possibly due to very low mediator concentrations 
and methodological issues discussed above.
The concentration of IL-1β in EBC was high-
er in COPD than in non-smokers but lower than 
in smokers, with no correlation with lung func-
tion.55 Increased EBC IL-6 level was measured in 
COPD by some authors;81 however, another study 
showed a lower concentration of this cytokine.55 
Treatment with tiotropium did not affect exhaled 
IL-6 levels.74 Similar 25 and lower 55 levels of IL-8 
were reported in stable COPD compared to health. 
There was a significant correlation between IL-8 
and lung function in one study but another re-
ported no correlation.82 IL-8 levels significantly 
increased during exacerbation in some 26, 83 and 
remained unchanged in other 25 studies. IL-10 was 
lower in COPD compared to smokers,82 however 
another study showed no difference.55 il-12 was 
increased in COPD;84 however, another study 
reported lower levels of IL-12p70 compared to 
smokers.82 There was no correlation with lung 
function.82
Studies on the pro-inflammatory cytokine 
ex-smokers, and ICS therapy was not associated 
with altered mediator concentration either.75 a 
novel fast method of capillary electrophoresis 
could detect increased concentrations of both ni-
trate and nitrite in EBC from patients with COPD 
compared to young, non-smoking controls in a 
pilot study.76 This was also shown by another 
study using a different detection method.77 in 
addition, EBC nitrosothiol concentration was el-
evated in ex-smoking COPD patients compared 
to non-smoking controls, but not to smokers.2 
Furthermore, increased EBC nitrosothiol level 
was reported in retired coal workers with COPD 
compared to those with a similar history of in-
haled exposure but no COPD.63
Measurement of nitrative stress markers are 
sensitive to external contamination, and sensi-
tive detection methods are needed for reliable 
assessment.
Arachidonic acid metabolites
Arachidonic acid metabolites, including pros-
tanoids, tromboxanes and leukotrienes, are in-
volved in airway inflammation characterizing 
COPD. They were investigated in EBC either 
separately with EIAs or using complex analytics, 
such as mass spectrometry. The latter technique 
provided evidence of altered profile of arachi-
donic acid metabolites in COPD.78
The most frequently investigated arachidonic 
acid metabolite in EBC is LTB4, which is a potent 
chemoattractant for neutrophil cells. All studies 
showed elevated EBC LTB4 concentrations in 
COPD compared to controls.65, 72, 78-80 although 
there was no further increase in mediator con-
centration during exacerbation,80 LTB4 level de-
creased during recovery from a relapse.65, 80 in 
addition, no difference in EBC LTB4 levels was 
reported between COPD patients with and with-
out cardiovascular disease.72 EBC LTB4 concen-
tration was not altered by inhaled corticosteroid 
(ICS) treatment.73
Prostaglandin E2 (PGE2) pathway is impli-
cated in the resolution of airway inflammation. 
Interestingly, higher EBC PGE2 concentrations 
were reported in COPD 65, 78, 79 compared to 
health without a change during COPD acute ex-
acerbation.65
EBC cys-LT levels were elevated in patients 
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ase-1 were increased in COPD, and heightened 
during exacerbation.92 However, EBC MMP9 
concentration was below the detection limit in 
another study using a similar EIA platform for 
detection.91
Detection of proteins including cytokines, 
chemokines and circulating receptors in EBC 
seems unreliable with immune assays used in 
previous reports, as implicated by the contradic-
tory findings on these markers in stable and ex-
acerbated COPD.
“Omics” profiles detected in EBC
The “omics” technology offers the potential to 
detect a multiparametric response to physiologi-
cal and pathophysiological stimuli in health and 
disease. It can generate a profile of multiple vari-
ables which have the potential to better identify 
disease mechanisms than single markers. The 
main advantage of this approach is its hypothe-
sis-free nature, which gives ground to the iden-
tification of novel substances, previously not 
linked with disease pathomechanism. The appli-
cation of “omics” approach in EBC has mostly 
included analysis of metabolic compounds (me-
tabolomics) and proteins (proteomics). Despite 
the current enthusiasm, it is worth taking into ac-
count that the inherent methodology limitations 
such as dilution and not least mixed contribution 
from upper airways, mouth and salivary glands 
are likely to impact “omics” as well.
Metabolomic fingerprints of EBC gener-
ated by NMR spectroscopy followed by cluster 
analysis could differentiate patients with COPD 
from control smokers with very good accuracy 
(r2=99.9%).14, 20 in a very recent publication, 
NMR spectra obtained from patients with newly 
diagnosed COPD or asthma could distinguish be-
tween patients.20 A higher concentration of etha-
nol and methanol, while lower levels of formate 
and acetone/acetion were found in COPD. Their 
model was validated in a second set of patients 
with a sensitivity of 92.3% and a specificity of 
95%. Interestingly, metabolomic fingerprinting of 
EBC could identify the emphysematous subgroup 
within a cohort of COPD patients.93 in a pilot 
study, a method of on-site, fast capillary electro-
phoretic analysis of EBC allowed the detection 
of multiple metabolic products including acetate, 
TNF-α also reported conflicting findings. High-
er,81 similar,83, 85 or even lower 55, 82 levels of 
EBC TNF-α were shown in COPD. Cytokine 
concentration did not correlate with lung func-
tion 82, 85 and there was no difference in TNF-α in 
emphysema-dominant and non-emphysematous 
COPD patients.62 Treatment with tiotropium 74 
did not affect TNF-α levels in COPD patients. 
Furthermore, increased and unchanged concen-
trations of TNF-α were also reported during ex-
acerbation.83, 85
There was no difference in the level of GROα 
or CXCL1, a chemoattractant for neutrophils, 
between healthy and stable COPD subjects,80 
however another study reported lower levels in 
diseased subjects than controls.86 although there 
was no difference in EBC GROα levels between 
stable and exacerbated patients,80 the concentra-
tion the chemokine decreased during recovery 
from a flare-up.80
Surfactants are associated with host defence of 
the lung, which is compromised in COPD. In line 
with this, a study demonstrated lower levels of 
surfactant protein A (SP-A) in COPD compared 
to health, which directly correlated to lung func-
tion.87 However, a change in EBC SP-A concen-
tration in COPD was not confirmed by another 
group.23 Similarly, no difference in EBC surfac-
tant protein B was measured.23
Markers of recruitment and activation of neu-
trophil, monocyte and macrophages could be 
detected in the condensate fluid. Significantly 
elevated EBC concentration of myeloperoxi-
dase,36 secretory leukocyte protease inhibitor,36 
macrophage migration inhibitory factor,84 ran-
TES,84 sicaM-1 84, 88 were found in COPD. No 
change in the EBC level of monocyte chemotac-
tic protein-1,86 svcaM1,88 se-selectin,88 vascu-
lar endothelial growth factor,83 fibroblast growth 
factor-β,83 angiogenin,83 periostin 89 or alpha-
1-antitrypsin 90 was reported. However, alpha-
1-antitrypsin increased during exacerbation.90 
On the other hand, EBC IFN-γ concentration de-
creased in COPD.36
Matrix metalloproteases (MMP) degrade the 
pulmonary extracellular matrix, contributing to 
parenchymal destruction. Exhaled MMP8 con-
centration was lower,91 while the concentrations 
of MMP9 and the inhibitor of metalloprotein-
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Nucleic acids
It can be postulated that exhaled particles con-
tain live or dead pathogens originating from the 
lower airways, and they might also carry very 
small amounts of DNA and RNA fragments from 
resident and inflammatory cells within the lungs.
Bacterial DNA, but not viral RNA, was suc-
cessfully detected in EBC from exacerbated 
COPD patients. The profile of airway microor-
ganisms in EBC did not correlate with that found 
in sputum, suggesting different sampling sites 
for sputum and EBC and questioning the clinical 
relevance of analysing the condensate fluid for 
airway pathogens in COPD.96
The ratio of mitochondrial DNA to nuclear 
DNA, as a marker of oxidative stress, was found 
to be elevated in EBC from patients with stable 
COPD compared to control subjects.97 However, 
this study was biased by the unmatched smoking 
history between patients and controls.
MicroRNAs are small, non-coding nucleo-
tides, which modify post-transcriptional gene 
expression and they are dysregulated under in-
flammatory conditions including asthma and 
COPD. MicroRNAs can be found intracellularly 
and extracellularly in bodily fluids. The expres-
sion of 39 microRNAs was successfully mea-
sured in EBC from stable patients with allergic 
asthma, COPD and control subjects (unmatched 
smoking history to COPD patients). The authors 
identified 9 principal components from the ex-
pression data, which could distinguish controls 
from patient groups, but not patients with asthma 
from those with COPD.98 FEV1 was a major con-
founder in the analysis.
The number of studies on nucleic acids in 
EBC from patients with COPD is very limited. 
These observations suggest very low DNA and 
RNA content in EBC, and preliminary findings 
need further validation.
Conclusions
The collection of exhaled breath condensate is 
completely non-invasive, easily repeatable with-
in short time intervals, and constituents of the 
condensate fluid partly originate from the lower 
airways, showing potential for disease monitor-
lactate, propionate and butyrate.76 concentrations 
of acetate and propionate were increased in COPD 
compared to controls, however clinical character-
istics (age, smoking history) were not matched 
between the groups.
A protocol of using liquid chromatography 
and mass spectrometry for proteomic analysis 
was developed.94 The same group identified pro-
files of sets of proteins which identified COPD 
patients without emphysema, patients with em-
physema associated with alpha-1-antitrypsin de-
ficiency and control subjects.95 They partly vali-
dated these findings using other detection tech-
niques. Some identified proteins had not been 
previously linked with the diseases, giving new 
insight into disease pathomechanism. Important-
ly, >100 proteins were reproducibly identified in 
EBC from control subjects, making the first step 
to characterize the EBC proteome in health.13
Metabolomic and proteomic analysis of EBC 
samples needs sample preparation, advanced 
detection techniques and complex analysis al-
gorithms, which could limit their use in clini-
cal practice. However, optimized measurement 
protocols may facilitate understanding disease 
mechanisms and broaden the potential of EBC 
analysis.
Purinergic mediators
ATP is released from every cell to activate pu-
rinergic P2 receptors in an autocrine/paracrine 
fashion. ATP can be converted enzymatically 
into adenosine triphosphate (ADP), adenosine 
monophosphate (AMP) and then into adenos-
ine, mediators which also activate P2 and P1 
receptors. Receptor activation on epithelial and 
inflammatory cells within the airways induce 
ciliary beating, promotes inflammation but can 
also be involved in the resolution of inflamma-
tory processes.
ATP concentration in EBC did not change in 
COPD patients with an acute severe exacerba-
tion compared to smoking and non-smoking 
controls, and it was unchanged during convales-
cence.6 However, adenosine/urea and AMP/urea 
ratios were increased in stable COPD and corre-
lated with FEV1% predicted, suggesting that ATP 
degrades fast in airways, but its products can be 
used for monitoring of airway inflammation.47
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